RadNet, Inc.

NasdaqGM RDNT

RadNet, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD -227.78 M

RadNet, Inc. Net Cash Used For Investing Activities is USD -227.78 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 17.69% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

RadNet, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -276.72 M, a -49.54% change year over year.
RadNet, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -185.05 M, a 6.29% change year over year.
RadNet, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -197.47 M, a -110.60% change year over year.
RadNet, Inc. Net Cash Used For Investing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -93.76 M, a 41.08% change year over year.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

NasdaqGM: RDNT

RadNet, Inc.

CEO	Dr. Howard G. Berger M.D.
IPO Date	Jan. 3, 1997
Location	United States
Headquarters	1508, 1510 and 1516 Cotner Avenue
Employees	10,000
Sector	Health Care
Industries Hospitals & Clinics Medical Instruments

Description

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of images in the field of mammography, as well as AI solutions for lung and prostate cancer. As of December 31, 2021, it owned and managed 347 centers in Arizona, California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1981 and is headquartered in Los Angeles, California.

Key trends

Past 5 years